Developer docs
API playgroundTry for free, no card

Search company profiles

CSI Pharmacy

Full company profile

uuid000btql

Namestring
CSI Pharmacy
Legal namestring
CSI Pharmacy
Websiteurl
csipharmacy.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

CSI Pharmacy, founded in 2014 by James Sheets, PharmD, IgCP and headquartered in Nash, Texas, is a privately held specialty infusion pharmacy that delivers immunoglobulin (Ig) therapy — both intravenous (IVIg) and subcutaneous (SCIg) — and select specialty biologics to patients with rare and chronic diseases in their homes. The company describes itself as the largest nationwide independent specialty infusion pharmacy; it is licensed in all 50 states, operates eight specialty pharmacy locations across TX, MA, CT, OH, FL, and CA, and maintains a network of 400+ IgNS-certified home infusion nurses serving 4,000+ patients referred by 4,000+ physicians. CSI's core service bundle combines dispensing and home delivery of high-cost specialty drugs with in-home nursing, intake coordination, insurance verification and prior authorization, financial assistance navigation, patient advocacy, and continuous outcomes monitoring through its proprietary Clinical Outcomes 360° Program. The company carries URAC and ACHC accreditations and was the first multi-location specialty pharmacy to receive ACHC Distinction in Ig Therapy (jointly created with the Immunoglobulin National Society) in 2026.

The revenue model is built around recurring specialty pharmacy revenue: CSI bills insurance plans for Ig and biologic infusions as an in-network provider with most major payers, with prior authorization and benefit verification handled in-house. Revenue is supplemented by manufacturer copay programs and nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell, Patient Advocate Foundation, NORD) that reduce patient out-of-pocket costs and support continued therapy adherence. Pricing is not publicly disclosed. GTM is hybrid: enterprise field sales targeting neurologists, immunologists, and specialists via condition-specific enrollment forms; patient/community-led acquisition through disease-specific foundations, the 5,000+ member IVIG & SCIG Facebook support community, and patient conferences; plus content marketing via the company blog. Differentiation rests on IgNS-certified clinical staff, the Clinical Outcomes 360° outcomes program, all-50-state distribution, and reported patient metrics including an NPS of 98 (vs 76 industry average), 98% satisfaction with fill time, and 96% of patients stating they would be very unhappy to switch pharmacies.

Short descriptiontext

CSI Pharmacy is a privately held, nationwide specialty infusion pharmacy that delivers home-based IVIg, SCIg, and biologic therapies to 4,000+ patients with rare and chronic diseases, supported by 400+ IgNS-certified nurses and eight specialty pharmacy locations across the U.S.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNash, United States
HQ citystring
Nash
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty infusion pharmacy, home infusion therapy, immunoglobulin therapy, biologic medications, chronic disease care
Industry4 codes
1In-Home Infusion Pharmacy Support & Coordination
CodeHSABALAHPrimaryYes
2Injectables & Specialty Medication Support (e.g., insulin, biologics)
CodeHSABALAGPrimaryNo
3Home Infusion Therapy & IV Nursing Services
CodeHLADAFAGPrimaryNo
4Home Infusion Therapy Providers
CodeHLAFAEAEPrimaryNo
NAICS code1 code
  • Pharmacies and Drug Retailers456110
SIC code1 code
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Specialty Pharmacy Services
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Specialty Infusion Pharmacy Services
TypeSubscription Recurring
Description

CSI Pharmacy generates revenue through billing insurance plans for specialty infusion medications (Ig therapies and biologics), prior authorizations, and ongoing treatment coordination. The company is in-network with most major insurance providers and handles benefit verification and prior authorization on behalf of patients.

csipharmacy.com
2Financial Assistance Coordination
TypeManaged Services
Description

CSI helps patients access manufacturer assistance programs, nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell Foundation, Patient Advocate Foundation, NORD), and payment plans. While these services reduce patient burden, they facilitate treatment access and ongoing revenue.

csipharmacy.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details1 tier
1Insurance-based pricing with in-network provider arrangements
ModelSubscriptionBilling cadenceMonthly
Notes

CSI is in-network with most major insurance providers. Costs vary by insurance plan, medication, and treatment frequency. Prior authorization is typically required for specialty infusion therapies.

csipharmacy.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

CSI Pharmacy is a specialty infusion pharmacy that delivers home infusion immunoglobulin (Ig) therapy (IVIg and SCIg) and biologic therapies to patients with rare and chronic diseases. The service combines in-home IgNS-certified infusion nursing, specialty pharmacy dispensing, insurance and reimbursement coordination, intake services, patient advocacy, and financial assistance into an integrated care model. CSI is licensed in all 50 states and serves patients through provider referrals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 98% patient satisfaction with prescription fill time
+3 more records
Product overview1 text field

CSI Pharmacy is a specialty infusion pharmacy operating as a platform of integrated services rather than a single product. The core offering is Home Infusion Ig Therapy (IVIg and SCIg), supported by Specialty Infusion Pharmacy Services, Infusion Nursing Services, Intake Services, Insurance and Reimbursement Services, Patient Advocacy, and Financial Assistance Programs. The company also offers a portfolio of Ig medications (IVIg products like Gammagard, Gammaked, Privigen; SCIg products like Hizentra, Cuvitru, HyQvia) and Biologic Therapies (including Entyvio, Ocrevus, Vyvgart, Remicade) for treating rare and chronic diseases. A Clinical Outcomes 360° Program provides continuous monitoring and quality improvement. The service model is built around personalized, in-home care with dedicated care coordinators and IgNS-certified clinical staff.

Product and service11 records
1Home Infusion Ig Therapy (IVIg/SCIg)
2Specialty Infusion Pharmacy Services
3Infusion Nursing Services
CategoryCore Service - Nursing
Description

In-home nursing services providing expert Ig therapy administration by IgNS-certified nurses who deliver compassionate, personalized care tailored to each patient's unique needs.

4Intake Services
CategoryCore Service - Care Coordination
Description

Referral coordination services guiding patients through the infusion journey with insurance verification, personalized treatment planning, and scheduling support.

5Insurance and Reimbursement Services
CategoryCore Service - Reimbursement
Description

Insurance coordination services including benefit verification, prior authorization management, and appeals support to help patients navigate coverage for infusion therapy.

6Patient Advocacy
CategoryCore Service - Patient Advocacy
Description

Dedicated patient advocacy services providing education, emotional support, access to community resources, support groups, and financial assistance coordination.

7Financial Assistance Programs
CategoryCore Service - Financial Assistance
Description

Co-pay and financial assistance programs connecting patients with manufacturer assistance, nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell Foundation, Patient Advocate Foundation, NORD), and flexible payment plans to reduce out-of-pocket costs.

8Ig Medications (IVIg Products)
9Ig Medications (SCIg Products)
CategoryProduct - Immunoglobulin Therapy
Description

FDA-approved subcutaneous immune globulin products including Cutaquig 16.5%, Cuvitru 20%, Hizentra 20%, HyQvia 10% (facilitated SCIG), and Xembify 20%.

10Biologic Therapies
CategoryProduct - Biologic Therapy
Description

Specialty biologic medications for autoimmune, neuromuscular, and inflammatory conditions including Entyvio, Skyrizi, Stelara, Tremfya, Ocrevus, Soliris, Ultomiris, Vyvgart, Vyvgart Hytrulo, Remicade, and others.

11Bleeding Disorder Therapies
CategoryProduct - Bleeding Disorder Therapy
Description

Hemophilia and bleeding disorder treatments including Factor VIII products (Advate, Adynovate, Alphanate, Eloctate, Esperoct, Kogenate, Kovaltry, Novoeight, Nuwiq, Xyntha), Factor IX products (Alprolix, BeneFIX, Idelvion, Ixinity, Rixubis), and other factors (Feiba, Hemlibra, Humate-P, Novoseven RT, Obizur, Rebinyn, Recombinate, Wilate).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Immunoglobulin National Society (IgNS)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

CSI Pharmacy became the first multi-location specialty pharmacy to achieve ACHC Distinction in Ig Therapy in partnership with IgNS. CSI was also the first corporate member of IgNS, demonstrating deep commitment to advancing Ig therapy standards. IgNS provides certification for CSI's clinical staff (nurses and pharmacists) and collaborates on Ig therapy standards of care.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-27
Description

CSI Pharmacy achieved the first ACHC Distinction in Ig Therapy accreditation, jointly created by ACHC and IgNS. This prestigious accreditation recognizes CSI's commitment to improved patient outcomes, clinical excellence, staff expertise, and strong operational systems in delivering Ig therapy.

Strategic tierCoreTypeOthers
Description

CSI Pharmacy holds URAC Specialty Pharmacy accreditation, demonstrating compliance with rigorous quality standards for specialty pharmacy operations.

Strategic tierMinorTypeOthers
Description

James Sheets, CEO and Founder of CSI Pharmacy, serves as an advisory board member for Evive Biologics.

Strategic tierMinorTypeOthers
Description

James Sheets, CEO and Founder of CSI Pharmacy, serves as an advisory board member for the Myasthenia Gravis Hope Foundation.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest U.S. independent provider of home and alternate-site infusion services, offering home Ig therapy, specialty biologics, and home infusion nursing across all 50 states—CSI's most direct national-scale competitor. CSI's CSO Randy Broyles previously held executive roles at predecessor entities (Walgreens-Optioncare).

TypeDirect peer
Description

National home infusion company specializing in IVIg, SCIg, and other immunoglobulin therapies for chronic and rare diseases. Operates Ig-certified clinical staff and a similar provider-referral-driven model to CSI, making it a direct competitive peer in home Ig infusion.

TypeDirect peer
Description

Privately held specialty infusion provider offering home and alternate-site administration of specialty biologics and Ig therapy. Competes head-to-head with CSI for the same referring physician and patient segments across multiple states.

TypeBroad incumbent
Description

One of the largest U.S. specialty pharmacies, owned by Cigna's Evernorth/Express Scripts, distributing specialty biologics and Ig products. Represents the vertically integrated PBM-owned model that competes with independents like CSI through captive payer relationships.

TypeBroad incumbent
Description

Specialty and home infusion pharmacy arm of UnitedHealth Group's Optum, with national scale and direct in-network access through UnitedHealthcare. CSI's CSO Randy Broyles previously held executive roles at Optum Infusion Pharmacy, underscoring the competitive overlap.

TypeBroad incumbent
Description

CVS Health's home infusion and specialty pharmacy business, providing IVIg and other biologic infusions nationally. A vertically integrated incumbent competing for the same patient population and provider referrals as CSI.

TypeEmerging player
Description

Franchise-based home infusion network with locations across the U.S. offering specialty biologics, Ig therapy, and home infusion services. A partial-overlap competitor with a more decentralized model than CSI's centrally managed pharmacy locations.

TypeEmerging player
Description

Specialty home infusion pharmacy focused on immune globulin and other chronic disease therapies. Niche competitor with overlapping clinical focus in Ig therapy and similar referral-based patient acquisition model.

TypeEmerging player
Description

Specialty home infusion and enteral nutrition company providing Ig therapy and biologics in the home setting. Mid-size competitor with overlapping clinical and operational model in home-based specialty infusion.

TypeOthers
Description

Formerly one of the largest U.S. independent specialty pharmacies, now part of Optum. Listed here because of direct leadership lineage—CSI's CSO Randy Broyles previously held executive roles at Diplomat Specialty Infusion Group—and shared historical positioning as a large independent specialty pharmacy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CSI Pharmacy

Specialty Pharmacy Servicescsipharmacy.com

CSI Pharmacy is a privately held, nationwide specialty infusion pharmacy that delivers home-based IVIg, SCIg, and biologic therapies to 4,000+ patients with rare and chronic diseases, supported by 400+ IgNS-certified nurses and eight specialty pharmacy locations across the U.S.

What CSI Pharmacy does

CSI Pharmacy, founded in 2014 by James Sheets, PharmD, IgCP and headquartered in Nash, Texas, is a privately held specialty infusion pharmacy that delivers immunoglobulin (Ig) therapy — both intravenous (IVIg) and subcutaneous (SCIg) — and select specialty biologics to patients with rare and chronic diseases in their homes. The company describes itself as the largest nationwide independent specialty infusion pharmacy; it is licensed in all 50 states, operates eight specialty pharmacy locations across TX, MA, CT, OH, FL, and CA, and maintains a network of 400+ IgNS-certified home infusion nurses serving 4,000+ patients referred by 4,000+ physicians. CSI's core service bundle combines dispensing and home delivery of high-cost specialty drugs with in-home nursing, intake coordination, insurance verification and prior authorization, financial assistance navigation, patient advocacy, and continuous outcomes monitoring through its proprietary Clinical Outcomes 360° Program. The company carries URAC and ACHC accreditations and was the first multi-location specialty pharmacy to receive ACHC Distinction in Ig Therapy (jointly created with the Immunoglobulin National Society) in 2026.

The revenue model is built around recurring specialty pharmacy revenue: CSI bills insurance plans for Ig and biologic infusions as an in-network provider with most major payers, with prior authorization and benefit verification handled in-house. Revenue is supplemented by manufacturer copay programs and nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell, Patient Advocate Foundation, NORD) that reduce patient out-of-pocket costs and support continued therapy adherence. Pricing is not publicly disclosed. GTM is hybrid: enterprise field sales targeting neurologists, immunologists, and specialists via condition-specific enrollment forms; patient/community-led acquisition through disease-specific foundations, the 5,000+ member IVIG & SCIG Facebook support community, and patient conferences; plus content marketing via the company blog. Differentiation rests on IgNS-certified clinical staff, the Clinical Outcomes 360° outcomes program, all-50-state distribution, and reported patient metrics including an NPS of 98 (vs 76 industry average), 98% satisfaction with fill time, and 96% of patients stating they would be very unhappy to switch pharmacies.

CSI Pharmacy firmographics

Firmographics
Name
CSI Pharmacy
Legal name
CSI Pharmacy
Website
https://csipharmacy.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
CSI Pharmacy is a privately held, nationwide specialty infusion pharmacy that delivers home-based IVIg, SCIg, and biologic therapies to 4,000+ patients with rare and chronic diseases, supported by 400+ IgNS-certified nurses and eight specialty pharmacy locations across the U.S.
Ownership category
akta.pro rank

CSI Pharmacy industry classification

Industry
Product category
Specialty Pharmacy Services
NAICS
Pharmacies and Drug Retailers (456110)
SIC
Retail-Drug Stores And Proprietary Stores (5912)
akta.pro primary industry
In-Home Infusion Pharmacy Support & Coordination (HSABALAH)
akta.pro secondary industries
Injectables & Specialty Medication Support (e.g., insulin, biologics) (HSABALAG), Home Infusion Therapy & IV Nursing Services (HLADAFAG), Home Infusion Therapy Providers (HLAFAEAE)

Keywords

  • Specialty infusion pharmacy
  • Home infusion therapy
  • Immunoglobulin therapy
  • Biologic medications
  • Chronic disease care

Where CSI Pharmacy is headquartered

Location

Headquarters

HQ city
Nash
HQ country
United States
HQ region
North America

Offices8 records

Markets served

CSI Pharmacy business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Specialty Infusion Pharmacy Services: CSI Pharmacy generates revenue through billing insurance plans for specialty infusion medications (Ig therapies and biologics), prior authorizations, and ongoing treatment coordination. The company is in-network with most major insurance providers and handles benefit verification and prior authorization on behalf of patients.
  2. Financial Assistance Coordination: CSI helps patients access manufacturer assistance programs, nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell Foundation, Patient Advocate Foundation, NORD), and payment plans. While these services reduce patient burden, they facilitate treatment access and ongoing revenue.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyInsurance-based pricing with in-network provider arrangements

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

CSI Pharmacy product offering

Product offering

Core offering

CSI Pharmacy is a specialty infusion pharmacy that delivers home infusion immunoglobulin (Ig) therapy (IVIg and SCIg) and biologic therapies to patients with rare and chronic diseases. The service combines in-home IgNS-certified infusion nursing, specialty pharmacy dispensing, insurance and reimbursement coordination, intake services, patient advocacy, and financial assistance into an integrated care model. CSI is licensed in all 50 states and serves patients through provider referrals.

Product overview

CSI Pharmacy is a specialty infusion pharmacy operating as a platform of integrated services rather than a single product. The core offering is Home Infusion Ig Therapy (IVIg and SCIg), supported by Specialty Infusion Pharmacy Services, Infusion Nursing Services, Intake Services, Insurance and Reimbursement Services, Patient Advocacy, and Financial Assistance Programs. The company also offers a portfolio of Ig medications (IVIg products like Gammagard, Gammaked, Privigen; SCIg products like Hizentra, Cuvitru, HyQvia) and Biologic Therapies (including Entyvio, Ocrevus, Vyvgart, Remicade) for treating rare and chronic diseases. A Clinical Outcomes 360° Program provides continuous monitoring and quality improvement. The service model is built around personalized, in-home care with dedicated care coordinators and IgNS-certified clinical staff.

Differentiator

Problem solved

Functional benefit

Products and services

  • Home Infusion Ig Therapy (IVIg/SCIg)
  • Specialty Infusion Pharmacy Services
  • Infusion Nursing Services In-home nursing services providing expert Ig therapy administration by IgNS-certified nurses who deliver compassionate, personalized care tailored to each patient's unique needs.
  • Intake Services Referral coordination services guiding patients through the infusion journey with insurance verification, personalized treatment planning, and scheduling support.
  • Insurance and Reimbursement Services Insurance coordination services including benefit verification, prior authorization management, and appeals support to help patients navigate coverage for infusion therapy.
  • Patient Advocacy Dedicated patient advocacy services providing education, emotional support, access to community resources, support groups, and financial assistance coordination.
  • Financial Assistance Programs Co-pay and financial assistance programs connecting patients with manufacturer assistance, nonprofit foundation grants (PAN Foundation, The Assistance Fund, Healthwell Foundation, Patient Advocate Foundation, NORD), and flexible payment plans to reduce out-of-pocket costs.
  • Ig Medications (IVIg Products)
  • Ig Medications (SCIg Products) FDA-approved subcutaneous immune globulin products including Cutaquig 16.5%, Cuvitru 20%, Hizentra 20%, HyQvia 10% (facilitated SCIG), and Xembify 20%.
  • Biologic Therapies Specialty biologic medications for autoimmune, neuromuscular, and inflammatory conditions including Entyvio, Skyrizi, Stelara, Tremfya, Ocrevus, Soliris, Ultomiris, Vyvgart, Vyvgart Hytrulo, Remicade, and others.
  • Bleeding Disorder Therapies Hemophilia and bleeding disorder treatments including Factor VIII products (Advate, Adynovate, Alphanate, Eloctate, Esperoct, Kogenate, Kovaltry, Novoeight, Nuwiq, Xyntha), Factor IX products (Alprolix, BeneFIX, Idelvion, Ixinity, Rixubis), and other factors (Feiba, Hemlibra, Humate-P, Novoseven RT, Obizur, Rebinyn, Recombinate, Wilate).

Quantifiable outcome

  • 98% patient satisfaction with prescription fill time
  • +3 more outcomes

Companies that use CSI Pharmacy

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

CSI Pharmacy technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

CSI Pharmacy partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Immunoglobulin National Society (IgNS)coreStrategic or Co-development Partner · 27 April 2026CSI Pharmacy became the first multi-location specialty pharmacy to achieve ACHC Distinction in Ig Therapy in partnership with IgNS. CSI was also the first corporate member of IgNS, demonstrating deep commitment to advancing Ig therapy standards. IgNS provides certification for CSI's clinical staff (nurses and pharmacists) and collaborates on Ig therapy standards of care.
  • Accreditation Commission for Health Care (ACHC)coreStrategic or Co-development Partner · 27 April 2026CSI Pharmacy achieved the first ACHC Distinction in Ig Therapy accreditation, jointly created by ACHC and IgNS. This prestigious accreditation recognizes CSI's commitment to improved patient outcomes, clinical excellence, staff expertise, and strong operational systems in delivering Ig therapy.
  • URACcoreOthersCSI Pharmacy holds URAC Specialty Pharmacy accreditation, demonstrating compliance with rigorous quality standards for specialty pharmacy operations.
  • Evive BiologicsminorOthersJames Sheets, CEO and Founder of CSI Pharmacy, serves as an advisory board member for Evive Biologics.
  • Myasthenia Gravis Hope FoundationminorOthersJames Sheets, CEO and Founder of CSI Pharmacy, serves as an advisory board member for the Myasthenia Gravis Hope Foundation.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

CSI Pharmacy competitors and assessment

Company assessment

Direct peers

  • Option Care Health: Largest U.S. independent provider of home and alternate-site infusion services, offering home Ig therapy, specialty biologics, and home infusion nursing across all 50 states—CSI's most direct national-scale competitor. CSI's CSO Randy Broyles previously held executive roles at predecessor entities (Walgreens-Optioncare).
  • KabaFusion: National home infusion company specializing in IVIg, SCIg, and other immunoglobulin therapies for chronic and rare diseases. Operates Ig-certified clinical staff and a similar provider-referral-driven model to CSI, making it a direct competitive peer in home Ig infusion.
  • Soleo Health: Privately held specialty infusion provider offering home and alternate-site administration of specialty biologics and Ig therapy. Competes head-to-head with CSI for the same referring physician and patient segments across multiple states.

Broad incumbents

  • Accredo (Express Scripts/Evernorth): One of the largest U.S. specialty pharmacies, owned by Cigna's Evernorth/Express Scripts, distributing specialty biologics and Ig products. Represents the vertically integrated PBM-owned model that competes with independents like CSI through captive payer relationships.
  • OptumRx (Optum Infusion Pharmacy): Specialty and home infusion pharmacy arm of UnitedHealth Group's Optum, with national scale and direct in-network access through UnitedHealthcare. CSI's CSO Randy Broyles previously held executive roles at Optum Infusion Pharmacy, underscoring the competitive overlap.
  • Coram CVS Specialty Infusion Services: CVS Health's home infusion and specialty pharmacy business, providing IVIg and other biologic infusions nationally. A vertically integrated incumbent competing for the same patient population and provider referrals as CSI.

Emerging players

  • Vital Care Infusion Services: Franchise-based home infusion network with locations across the U.S. offering specialty biologics, Ig therapy, and home infusion services. A partial-overlap competitor with a more decentralized model than CSI's centrally managed pharmacy locations.
  • Nufactor: Specialty home infusion pharmacy focused on immune globulin and other chronic disease therapies. Niche competitor with overlapping clinical focus in Ig therapy and similar referral-based patient acquisition model.
  • PromptCare (PromptCare Infusion / InTouch Pharmacy): Specialty home infusion and enteral nutrition company providing Ig therapy and biologics in the home setting. Mid-size competitor with overlapping clinical and operational model in home-based specialty infusion.

Others

  • Diplomat Pharmacy (now Optum Specialty Infusion): Formerly one of the largest U.S. independent specialty pharmacies, now part of Optum. Listed here because of direct leadership lineage—CSI's CSO Randy Broyles previously held executive roles at Diplomat Specialty Infusion Group—and shared historical positioning as a large independent specialty pharmacy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

CSI Pharmacy social profiles

Digital presence

CSI Pharmacy compliance and trust

Trust signal

Compliance3 records

CSI Pharmacy financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CSI Pharmacy leadership team

Management profile

Number of profiles

Profiles8 records

CSI Pharmacy funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CSI Pharmacy M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CSI Pharmacy

What does CSI Pharmacy do?

CSI Pharmacy is a specialty infusion pharmacy that delivers home infusion immunoglobulin (Ig) therapy (IVIg and SCIg) and biologic therapies to patients with rare and chronic diseases. The service combines in-home IgNS-certified infusion nursing, specialty pharmacy dispensing, insurance and reimbursement coordination, intake services, patient advocacy, and financial assistance into an integrated care model. CSI is licensed in all 50 states and serves patients through provider referrals.

Is CSI Pharmacy a public or private company?

CSI Pharmacy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CSI Pharmacy founded?

CSI Pharmacy was founded in 2014. It employs 51 to 100 people.

Where is CSI Pharmacy based?

CSI Pharmacy is headquartered in Nash, United States, in the North America region.

How does CSI Pharmacy make money?

Two revenue lines are on record. Specialty Infusion Pharmacy Services are the primary driver. The others are financial Assistance Coordination.

Who are CSI Pharmacy's main competitors?

Direct peers on record are Option Care Health, KabaFusion and Soleo Health. Broad incumbents are Accredo (Express Scripts/Evernorth), OptumRx (Optum Infusion Pharmacy) and Coram CVS Specialty Infusion Services. Emerging players are Vital Care Infusion Services, Nufactor and PromptCare (PromptCare Infusion / InTouch Pharmacy). Diplomat Pharmacy (now Optum Specialty Infusion) is listed as an others.

Does CSI Pharmacy have an API?

No public API is recorded for CSI Pharmacy.

What industry is CSI Pharmacy in?

CSI Pharmacy's product category is Specialty Pharmacy Services. Its primary akta.pro industry code is HSABALAH, In-Home Infusion Pharmacy Support & Coordination, with a secondary code of HSABALAG, Injectables & Specialty Medication Support (e.g., insulin, biologics). Its NAICS code is 456110 and its SIC code is 5912.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCSI Pharmacy Becomes First Multi-Location Specialty Pharmacy to Achieve ACHC Distinction in Ig Therapy in Partnership with IgNSCSI Pharmacy has become the first multi-location specialty pharmacy to achieve the Distinction in Immunoglobulin (Ig) Therapy accreditation from the Accreditation Commission for Health Care (ACHC) and the Immunoglobulin National Society (IgNS), awarded across its West Chester, Ohio; Enfield, Connecticut; and Nash, Texas locations. The distinction recognizes the organization's commitment to improved patient outcomes, clinical excellence, staff expertise, and strong operational systems in delivering Ig therapy. This accreditation represents a significant industry milestone, offering patients and providers a meaningful standard for identifying specialty infusion pharmacies meeting the highest level of care.PR NewswireCSI Pharmacy Receives 2026 Top Workplaces Culture Excellence Award for Employee AppreciationCSI Pharmacy, a nationwide specialty infusion pharmacy headquartered in Nash, Texas, was named a 2026 Top Workplaces Culture Excellence winner by Energage for employee appreciation. The award is based on feedback from research-backed employee engagement surveys administered to staff and recognizes organizations that demonstrate gratitude for employee efforts and foster motivated workplaces. The company attributes the recognition to its patient-centered mission and culture of valuing team members across all roles.PR NewswireCSI Pharmacy Leads the Way in Ig CertificationCSI Pharmacy, a Texas-based specialty infusion pharmacy, announced that 14 of its nurses and pharmacists obtained immunoglobulin (Ig) certification through the Immunoglobulin National Society (IgNS) in November. The company, which was the first corporate member of IgNS, now leads the industry in Ig certifications, positioning itself as the standard of excellence in Ig therapy for patients with rare and chronic diseases. CSI Pharmacy is licensed to dispense in 49 states plus D.C. and was founded in 2014 with a mission to advance Ig therapy administration standards.PR NewswireCSI Pharmacy Announces Limited Distribution Agreement for GammaplexCSI Pharmacy, an independent national specialty pharmacy headquartered in Texas, announced a limited distribution agreement with Bio Products Laboratory (BPL) for the immune globulin product Gammaplex, enabling the company to dispense all FDA-approved immune globulin products. The partnership is expected to diversify CSI Pharmacy's portfolio and strengthen its supply chain for patients with chronic and rare illnesses, with stocking anticipated to begin immediately. Founded in 2014, CSI Pharmacy currently operates under licenses in 48 states plus Washington, D.C.